RT Journal Article
SR Electronic
T1 Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1308
OP 1321
DO 10.1183/13993003.00779-2015
VO 46
IS 5
A1 Shaw, Dominick E.
A1 Sousa, Ana R.
A1 Fowler, Stephen J.
A1 Fleming, Louise J.
A1 Roberts, Graham
A1 Corfield, Julie
A1 Pandis, Ioannis
A1 Bansal, Aruna T.
A1 Bel, Elisabeth H.
A1 Auffray, Charles
A1 Compton, Chris H.
A1 Bisgaard, Hans
A1 Bucchioni, Enrica
A1 Caruso, Massimo
A1 Chanez, Pascal
A1 Dahlén, Barbro
A1 Dahlen, Sven-Erik
A1 Dyson, Kerry
A1 Frey, Urs
A1 Geiser, Thomas
A1 Gerhardsson de Verdier, Maria
A1 Gibeon, David
A1 Guo, Yi-ke
A1 Hashimoto, Simone
A1 Hedlin, Gunilla
A1 Jeyasingham, Elizabeth
A1 Hekking, Pieter-Paul W.
A1 Higenbottam, Tim
A1 Horváth, Ildikó
A1 Knox, Alan J.
A1 Krug, Norbert
A1 Erpenbeck, Veit J.
A1 Larsson, Lars X.
A1 Lazarinis, Nikos
A1 Matthews, John G.
A1 Middelveld, Roelinde
A1 Montuschi, Paolo
A1 Musial, Jacek
A1 Myles, David
A1 Pahus, Laurie
A1 Sandström, Thomas
A1 Seibold, Wolfgang
A1 Singer, Florian
A1 Strandberg, Karin
A1 Vestbo, Jorgen
A1 Vissing, Nadja
A1 von Garnier, Christophe
A1 Adcock, Ian M.
A1 Wagers, Scott
A1 Rowe, Anthony
A1 Howarth, Peter
A1 Wagener, Ariane H.
A1 Djukanovic, Ratko
A1 Sterk, Peter J.
A1 Chung, Kian Fan
YR 2015
UL https://publications.ersnet.org//content/46/5/1308.abstract
AB U-BIOPRED is a European Union consortium of 20 academic institutions, 11 pharmaceutical companies and six patient organisations with the objective of improving the understanding of asthma disease mechanisms using a systems biology approach.This cross-sectional assessment of adults with severe asthma, mild/moderate asthma and healthy controls from 11 European countries consisted of analyses of patient-reported outcomes, lung function, blood and airway inflammatory measurements.Patients with severe asthma (nonsmokers, n=311; smokers/ex-smokers, n=110) had more symptoms and exacerbations compared to patients with mild/moderate disease (n=88) (2.5 exacerbations versus 0.4 in the preceding 12 months; p<0.001), with worse quality of life, and higher levels of anxiety and depression. They also had a higher incidence of nasal polyps and gastro-oesophageal reflux with lower lung function. Sputum eosinophil count was higher in severe asthma compared to mild/moderate asthma (median count 2.99% versus 1.05%; p=0.004) despite treatment with higher doses of inhaled and/or oral corticosteroids.Consistent with other severe asthma cohorts, U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment. It is well suited to identify asthma phenotypes using the array of “omic” datasets that are at the core of this systems medicine approach.Severe asthma results in more airway inflammation, worse symptoms and lower lung function, despite increased therapy http://ow.ly/QznR3